175 related articles for article (PubMed ID: 37172201)
1. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
Chang Y; Keramatnia F; Ghate PS; Nishiguchi G; Gao Q; Iacobucci I; Yang L; Chepyala D; Mishra A; High AA; Goto H; Akahane K; Peng J; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2023 Aug; 142(7):629-642. PubMed ID: 37172201
[TBL] [Abstract][Full Text] [Related]
2. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
3. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Hansen JD; Correa M; Alexander M; Nagy M; Huang D; Sapienza J; Lu G; LeBrun LA; Cathers BE; Zhang W; Tang Y; Ammirante M; Narla RK; Piccotti JR; Pourdehnad M; Lopez-Girona A
J Med Chem; 2021 Feb; 64(4):1835-1843. PubMed ID: 33591756
[TBL] [Abstract][Full Text] [Related]
4. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
5. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
Nishiguchi G; Keramatnia F; Min J; Chang Y; Jonchere B; Das S; Actis M; Price J; Chepyala D; Young B; McGowan K; Slavish PJ; Mayasundari A; Jarusiewicz JA; Yang L; Li Y; Fu X; Garrett SH; Papizan JB; Kodali K; Peng J; Pruett Miller SM; Roussel MF; Mullighan C; Fischer M; Rankovic Z
J Med Chem; 2021 Jun; 64(11):7296-7311. PubMed ID: 34042448
[TBL] [Abstract][Full Text] [Related]
6. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells.
Sellar RS; Sperling AS; Słabicki M; Gasser JA; McConkey ME; Donovan KA; Mageed N; Adams DN; Zou C; Miller PG; Dutta RK; Boettcher S; Lin AE; Sandoval B; Quevedo Barrios VA; Kovalcik V; Koeppel J; Henderson EK; Fink EC; Yang L; Chan A; Pokharel SP; Bergstrom EJ; Burt R; Udeshi ND; Carr SA; Fischer ES; Chen CW; Ebert BL
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35763353
[TBL] [Abstract][Full Text] [Related]
7. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
8. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Lier S; Sellmer A; Orben F; Heinzlmeir S; Krauß L; Schneeweis C; Hassan Z; Schneider C; Patricia Gloria Schäfer A; Pongratz H; Engleitner T; Öllinger R; Kuisl A; Bassermann F; Schlag C; Kong B; Dove S; Kuster B; Rad R; Reichert M; Wirth M; Saur D; Mahboobi S; Schneider G
Bioorg Chem; 2022 Feb; 119():105505. PubMed ID: 34838332
[TBL] [Abstract][Full Text] [Related]
9. Protein Degradation via CRL4
Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
[TBL] [Abstract][Full Text] [Related]
10. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
11. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 2-carboxy indole derivatives as potent and selective anti-leukemic agents.
Cury NM; Capitão RM; Almeida RDCB; Artico LL; Corrêa JR; Simão Dos Santos EF; Yunes JA; Correia CRD
Eur J Med Chem; 2019 Nov; 181():111570. PubMed ID: 31408809
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
14. CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Ding H; Vincelette ND; McGehee CD; Kohorst MA; Koh BD; Venkatachalam A; Meng XW; Schneider PA; Flatten KS; Peterson KL; Correia C; Lee SH; Patnaik M; Webster JA; Ghiaur G; Smith BD; Karp JE; Pratz KW; Li H; Karnitz LM; Kaufmann SH
Cancer Res; 2021 May; 81(10):2666-2678. PubMed ID: 33414171
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity of docetaxel in childhood acute leukemias.
Consolini R; Pui CH; Behm FG; Raimondi SC; Campana D
J Clin Oncol; 1998 Mar; 16(3):907-13. PubMed ID: 9508172
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells.
Ito C; Ribeiro RC; Behm FG; Raimondi SC; Pui CH; Campana D
Blood; 1998 Feb; 91(3):1001-7. PubMed ID: 9446662
[TBL] [Abstract][Full Text] [Related]
18. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Zou J; Jones RJ; Wang H; Kuiatse I; Shirazi F; Manasanch EE; Lee HC; Sullivan R; Fung L; Richard N; Erdman P; Torres E; Hecht D; Lam I; McElwee B; Chourasia AH; Chan KWH; Mercurio F; Stirling DI; Orlowski RZ
J Mol Med (Berl); 2020 Aug; 98(8):1161-1173. PubMed ID: 32632752
[TBL] [Abstract][Full Text] [Related]
19. Chemokines and relapses in childhood acute lymphoblastic leukemia: A role in migration and in resistance to antileukemic drugs.
Gómez AM; Martínez C; González M; Luque A; Melen GJ; Martínez J; Hortelano S; Lassaletta Á; Madero L; Ramírez M
Blood Cells Mol Dis; 2015 Oct; 55(3):220-7. PubMed ID: 26227851
[TBL] [Abstract][Full Text] [Related]
20. TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.
Mendivil-Perez M; Velez-Pardo C; Quiroz-Duque LM; Restrepo-Rincon A; Valencia-Zuluaga NA; Jimenez-Del-Rio M
Biometals; 2022 Aug; 35(4):741-758. PubMed ID: 35635647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
